Review
Radiology, Nuclear Medicine & Medical Imaging
Giuseppe Mamone, Settimo Caruso, Mariapina Milazzo, Giorgia Porrello, Ambra Di Piazza, Giovanni Gentile, Vincenzo Carollo, Francesca Crino, Gianluca Marrone, Gianvincenzo Sparacia, Luigi Maruzzelli, Roberto Miraglia, Salvatore Gruttadauria
Summary: Liver transplantation provides the best survival benefit for hepatocellular carcinoma (HCC) patients who cannot undergo resection. The Milan criteria have been developed to select suitable candidates for transplantation, aiming to improve survival and reduce the risk of HCC recurrence. However, up to 20% of cases experience HCC recurrence after transplantation, posing a significant challenge due to poor prognosis. Various extended criteria have been proposed to accommodate the increasing demand for organs and the associated higher risk of recurrence. Radiologists need to be aware of the possibility of HCC recurrence involving multiple organs after transplantation. Understanding the location and radiologic appearance of recurrent HCC is crucial for choosing the most appropriate therapy.
INSIGHTS INTO IMAGING
(2023)
Article
Medicine, General & Internal
Indah Jamtani, Kwang-Woong Lee, Yunhee Choi, YoungRok Choi, Jeong-Moo Lee, Eui-Soo Han, Kwangpyo Hong, Gyu-Seong Choi, Jong Man Kim, Nam-Joon Yi, Suk Kyun Hong, Jeik Byun, Su Young Hong, Sanggyeun Suh, Jae-Won Joh, Kyung-Suk Suh
Summary: This study aimed to develop a tailored prediction model of HCC-specific survival after transplantation, validated internally and externally. By combining multiple risk factors, the model showed good accuracy in predicting HCC-specific survival tailored for patients undergoing transplantation. The calculated SALT predictor provided accurate information on expected survival rates based on risk scores and specific characteristics.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo
Summary: Recurrence of hepatocellular carcinoma after liver transplantation is a major concern, with poor prognosis and uncertainty in management. There is currently lack of specific surveillance strategy and sufficient data to support immunosuppressive drugs and adjuvant therapy.
Review
Gastroenterology & Hepatology
Sang Jin Kim, Jong Man Kim
Summary: Liver transplantation is an effective treatment for hepatocellular carcinoma, but some patients still experience recurrence after transplantation. Prediction models for HCC recurrence after transplantation have been published, but a standard has not been established. This review summarizes the latest prediction models for HCC recurrence after liver transplantation, focusing on radiologic, serologic, and pathologic factors, and includes studies on living donor and deceased donor transplantation.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Domitille Erard, Francois Villeret, Yasmina Chouik, Olivier Guillaud, Jean-Yves Scoazec, Cyrielle Caussy, Emmanuel Disse, Olivier Boillot, Valerie Hervieu, Jerome Dumortier
Summary: The study found that DAFLD has emerged as an indication for LT. After LT, DAFLD patients' liver graft disease is significantly influenced by features of metabolic syndrome, different from ALD patients and more similar to NAFLD patients.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Ao Huang, De-Zhen Guo, Xuan Zhang, Ying Sun, Shi-Yu Zhang, Xin Zhang, Xiu-Tao Fu, Yu-Peng Wang, Guo-Huan Yang, Qi-Man Sun, Yi-Feng He, Kang Song, Xiao-Wu Huang, Xin-Rong Yang, Wei-Ren Liu, Zhen-Bin Ding, Ying-Hong Shi, Jia Fan, Jian Zhou
Summary: This study reveals that ctDNA can effectively detect minimal residual disease (MRD) and predict tumor recurrence in liver cancer patients undergoing liver transplantation. The mutational profiles of ctDNA are highly concordant with those of tumor tissues. Positive ctDNA status is associated with higher recurrence rate and shorter recurrence-free survival. Serial monitoring of ctDNA can predict recurrence ahead of imaging evidence and serum tumor biomarkers.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Incheon Kang, Jae Geun Lee, Sung Hoon Choi, Hyun Jeong Kim, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo
Summary: EVR in combination with CNIs may prolong long-term survival in patients undergoing LT for HCC, with the EVR group showing more aggressive tumor biology characteristics such as a higher number of tumors.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Claudia Maccali, Aline L. Chagas, Ilka Boin, Emilio Quinonez, Sebastian Marciano, Mario Vilatoba, Adriana Varon, Margarita Anders, Sergio Hoyos Duque, Agnaldo S. Lima, Josemaria Menendez, Martin Padilla-Machaca, Jaime Poniachik, Rodrigo Zapata, Martin Maraschio, Ricardo Chong Menendez, Linda Munoz, Diego Arufe, Rodrigo Figueroa, Alejandro Soza, Martin Fauda, Simone R. Perales, Rodrigo Vergara Sandoval, Carla Bermudez, Oscar Beltran, Isabel Arenas Hoyos, Lucas McCormack, Francisco Juan Mattera, Adrian Gadano, Jose H. Parente Garcia, Claudia Megumi Tani, Luiz Augusto Carneiro D'Albuquerque, Flair J. Carrilho, Marcelo Silva, Federico Pinero
Summary: This study evaluated the post-recurrence survival (PRS) of HCC patients after liver transplantation, finding that early recurrence, sorafenib therapy, and surgery/TACE treatment were associated with improved survival rates. Any treatment, sorafenib therapy, and surgery/TACE treatment all significantly improved PRS.
LIVER INTERNATIONAL
(2021)
Article
Surgery
Thijmen Visseren, Nicole Stephanie Erler, Wojciech Grzegorz Polak, Rene Adam, Vincent Karam, Florian Wolfgang Rudolf Vondran, Bo-Goran Ericzon, Douglas Thorburn, Jan Nicolaas Maria IJzermans, Andreas Paul, Frans van der Heide, Pavel Taimr, Petr Nemec, Jacques Pirenne, Renato Romagnoli, Herold Johnny Metselaar, Sarwa Darwish Murad
Summary: Recurrence of PSC after liver transplantation has a significant negative impact on both graft and patient survival, leading to a higher number of re-transplants and a 33% decrease in 10-year graft survival.
TRANSPLANT INTERNATIONAL
(2021)
Article
Multidisciplinary Sciences
Ka Eun Kim, Dong Hyun Sinn, Moon Seok Choi, Honsoul Kim
Summary: HCC often recurs within a short period of time in patients who achieve a complete response to treatment with increased tumor marker levels, even if gadoxetic acid-enhanced MRI is negative. Short-term follow-up, including gadoxetic acid-enhanced MRI and systemic evaluation, is recommended.
Article
Oncology
Cheng-Maw Ho, Chih-Hsin Lee, Ming-Chia Lee, Jun-Fu Zhang, Chin-Hua Chen, Jann-Yuan Wang, Rey-Heng Hu, Po-Huang Lee
Summary: This study analyzed the survival of patients with post-transplant HCC recurrence, finding that early recurrence within two years after surgery had a poorer prognosis compared to late recurrence. Factors such as transplant era before 2008 and radiofrequency ablation were associated with better outcomes, while receiving sorafenib and radiotherapy were linked to poorer prognosis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Wei-Feng Qu, Meng-Xin Tian, Hong-Wei Lu, Yu-Fu Zhou, Wei-Ren Liu, Zheng Tang, Zhao Yao, Run Huang, Gui-Qi Zhu, Xi-Fei Jiang, Chen-Yang Tao, Yuan Fang, Jun Gao, Xiao-Ling Wu, Jia-Feng Chen, Qian-Fu Zhao, Rui Yang, Tian-Hao Chu, Jian Zhou, Jia Fan, Jin-Hua Yu, Ying-Hong Shi
Summary: This study developed a deep pathomics score (DPS) using deep learning to predict tumor recurrence after liver transplantation in hepatocellular carcinoma (HCC) patients. Immune cells were found to be the most significant histological structure related to post-LT recurrence. DPS performed well in recurrence prediction and identification of clinicopathological features.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Thijmen Visseren, Nicole S. Erler, Julie K. Heimbach, John E. Eaton, Nazia Selzner, Aliya Gulamhusein, Frans van Der Heide, Robert J. Porte, Bart van Hoek, Ian P. J. Alwayn, Herold J. Metselaar, Jan N. M. IJzermans, Sarwa Darwish Murad
Summary: This study aimed to identify risk factors for the recurrence of primary sclerosing cholangitis (rPSC) after liver transplantation (LT) in order to guide clinical management and prevention. The results showed that an increased inflammatory state before and after LT increased the incidence of rPSC. These inflammatory states are modifiable factors that could serve as targets for future studies and therapies.
Article
Radiology, Nuclear Medicine & Medical Imaging
Christiaan M. C. Serbanescu-Kele Apor De Zalan, Simeon J. S. Ruiter, Aad P. van den Berg, Jan Pieter Pennings, Koert P. de Jong
Summary: Thermal ablation (TA) has been proven to be an effective and repeatable therapy for both primary and recurrent HCC, with the majority of recurrences being treatable with curative intent. Some patients can achieve good outcomes with TA alone without the need for orthotopic liver transplantation (OLTx).
EUROPEAN RADIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Alessandro Parente, Mauricio Flores Carvalho, Janina Eden, Philipp Dutkowski, Andrea Schlegel
Summary: Tumor recurrence after liver transplantation is linked to multiple factors. Dynamic perfusion strategies, such as machine perfusion and endischemic organ improvement, have shown promising results in reducing complication and recurrence rates.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
